# Metabolic Syndrome-Driven Changes in Cardiac Lymphatic Endothelium: mRNA Expression and Emerging Questions

## TL;DR

This study explores how metabolic syndrome affects cardiac lymphatic endothelial cells through changes in gene expression, potentially offering new insights into heart failure treatment.

## Contribution

The study identifies transcriptional changes in cardiac lymphatic endothelial cells in response to metabolic syndrome in a mouse model.

## Key findings

- Cardiac lymphatic endothelial cells show transcriptional plasticity in response to metabolic syndrome.
- Gene expression changes in LECs suggest roles in lymphangiogenesis, metabolism, and ECM interactions.
- The findings highlight potential therapeutic targets for heart failure linked to metabolic syndrome.

## Abstract

Background/Objectives: Metabolic syndrome (MetS) conditions lead to structural and functional alterations in cardiomyocytes, microvasculature, and extracellular matrix (ECM), leading to myocardial fibrosis and impaired diastolic function. Cardiac lymphatic vessels (LVs) are increasingly recognized as key regulators of myocardial homeostasis, yet their response to MetS remains poorly understood. Therefore, we aimed to investigate transcriptional changes in cardiac lymphatic endothelial cells (LECs) in db/db mice, a well-established model of MetS. Methods: Using flow cytometry-sorted LECs and RT-PCR, we analyzed mRNA expression of genes involved in lymphangiogenesis, metabolism, mechanotransduction, immune cell trafficking, and ECM interactions. Results: Our findings show the transcriptional plasticity of cardiac LECs in response to MetS. Conclusions: Although our study is limited by the lack of protein-level validation and functional assays, our approach provides a broader interpretative framework and identifies potential directions for future research, including functional studies and pathway-specific investigations of the identified genes to assess their impact on lymphatic flow and cardiac function. Understanding LEC responses to metabolic stress may uncover novel therapeutic targets for heart failure associated with MetS.